相似文献
1
Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity.用 rVSV-EBOV-GP 进行埃博拉病毒的治疗性疫苗接种策略：固有免疫的作用。
Curr Opin Virol. 2021 Dec;51:179-189. doi: 10.1016/j.coviro.2021.10.007. Epub 2021 Nov 5.
2
Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.基于痘病毒的埃博拉病毒表达 GP 和 VP40 蛋白疫苗候选物的免疫原性和疗效的差异。
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.00363-18. Print 2018 Jun 1.
3
Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.VSV-EBOV 疫苗接种诱导的抗病毒先天免疫反应有助于快速保护。
mBio. 2019 May 28;10(3):e00597-19. doi: 10.1128/mBio.00597-19.
4
To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity.是B还是非B：重组水疱性口炎病毒载体埃博拉病毒糖蛋白疫苗（rVSV-EBOV-GP）的保护机制以及固有免疫和适应性免疫的作用
Microorganisms. 2020 Sep 25;8(10):1473. doi: 10.3390/microorganisms8101473.
5
Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine.非人类灵长类动物经肌肉注射而非鼻腔内接种一剂基于水疱性口炎病毒的疫苗可快速预防 COVID-19。
mBio. 2022 Feb 22;13(1):e0337921. doi: 10.1128/mbio.03379-21. Epub 2022 Jan 11.
6
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.抗体对于 rVSV/ZEBOV-GP 介导的非人类灵长类动物抵抗致死性埃博拉病毒攻击的保护是必要的。
Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1893-8. doi: 10.1073/pnas.1209591110. Epub 2013 Jan 14.
7
Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.埃博拉病毒糖蛋白Fc融合蛋白可保护豚鼠免受致死性攻击。
PLoS One. 2016 Sep 13;11(9):e0162446. doi: 10.1371/journal.pone.0162446. eCollection 2016.
8
Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.用高度减毒的重组水疱性口炎病毒载体进行疫苗接种可抵御致死剂量埃博拉病毒的攻击。
J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S443-51. doi: 10.1093/infdis/jiv316. Epub 2015 Jun 24.
9
An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.一种表达埃博拉病毒变体马科纳糖蛋白的腺病毒疫苗在豚鼠和非人灵长类动物中具有有效性。
J Infect Dis. 2016 Oct 15;214(suppl 3):S326-S332. doi: 10.1093/infdis/jiw250. Epub 2016 Aug 4.
10
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.单剂量减毒水泡性口炎病毒疫苗可保护灵长类动物免受埃博拉马科纳病毒感染。
Nature. 2015 Apr 30;520(7549):688-691. doi: 10.1038/nature14428. Epub 2015 Apr 8.
引用本文的文献
1
Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia.GamEvac-Combi（一种异源重组水疱性口炎病毒和重组腺病毒5型载体埃博拉疫苗）的安全性和免疫原性：在几内亚共和国和俄罗斯进行的一项随机对照多中心临床试验。
Front Immunol. 2025 Mar 20;16:1487039. doi: 10.3389/fimmu.2025.1487039. eCollection 2025.
2
Oral Immunization with rVSV Bivalent Vaccine Elicits Protective Immune Responses, Including ADCC, against Both SARS-CoV-2 and Influenza A Viruses.用重组水疱性口炎病毒二价疫苗进行口服免疫可引发针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）和甲型流感病毒的保护性免疫反应，包括抗体依赖的细胞介导的细胞毒性作用（ADCC）。
Vaccines (Basel). 2023 Aug 23;11(9):1404. doi: 10.3390/vaccines11091404.
本文引用的文献
1
Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013-16 West Africa epidemic.描述 2013-2016 年西非埃博拉疫情幸存者对埃博拉病毒糖蛋白的 T 细胞反应。
Nat Commun. 2021 Feb 19;12(1):1153. doi: 10.1038/s41467-021-21411-0.
2
Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine.人类对VSV载体埃博拉疫苗的转录组反应。
Vaccines (Basel). 2021 Jan 20;9(2):67. doi: 10.3390/vaccines9020067.
3
A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.一剂重组 VSV-∆G 棘突蛋白疫苗可提供针对 SARS-CoV-2 挑战的保护。
Nat Commun. 2020 Dec 16;11(1):6402. doi: 10.1038/s41467-020-20228-7.
4
Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study.埃博拉病毒病幸存者和接触者的纵向抗体和 T 细胞反应：一项观察性队列研究。
Lancet Infect Dis. 2021 Apr;21(4):507-516. doi: 10.1016/S1473-3099(20)30736-2. Epub 2020 Oct 13.
5
To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity.是B还是非B：重组水疱性口炎病毒载体埃博拉病毒糖蛋白疫苗（rVSV-EBOV-GP）的保护机制以及固有免疫和适应性免疫的作用
Microorganisms. 2020 Sep 25;8(10):1473. doi: 10.3390/microorganisms8101473.
6
Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment.先前接种 rVSV-ZEBOV 不会干扰但会提高暴露后抗体治疗的效果。
Nat Commun. 2020 Jul 27;11(1):3736. doi: 10.1038/s41467-020-17446-4.
7
Ebola-Specific CD8+ and CD4+ T-Cell Responses in Sierra Leonean Ebola Virus Survivors With or Without Post-Ebola Sequelae.塞拉利昂埃博拉幸存者有无埃博拉后遗症患者体内的埃博拉特异性 CD8+和 CD4+ T 细胞应答。
J Infect Dis. 2020 Oct 1;222(9):1488-1497. doi: 10.1093/infdis/jiaa268.
8
Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination.人源重组水疱性口炎病毒载体埃博拉病毒（rVSV-ZEBOV）疫苗接种后自然杀伤（NK）细胞的快速剂量依赖性调节及细胞因子反应
NPJ Vaccines. 2020 Apr 14;5(1):32. doi: 10.1038/s41541-020-0179-4. eCollection 2020.
9
The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms.埃博拉病毒糖蛋白及其在多种疫苗平台上的免疫反应。
Expert Rev Vaccines. 2020 Mar;19(3):267-277. doi: 10.1080/14760584.2020.1738225. Epub 2020 Mar 16.
10
Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola.在塞拉利昂引入埃博拉疫苗试验中，接受 rVSVΔ-ZEBOV-GP 埃博拉疫苗的女性的妊娠结局。
Emerg Infect Dis. 2020 Mar;26(3):541-548. doi: 10.3201/eid2603.191018. Epub 2020 Mar 17.
Zotero 插件